Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.
暂无分享,去创建一个
Olivier Lichtarge | Marek Kimmel | Beth M Beadle | Uma Giri | Jeffrey N Myers | Thomas O. McDonald | Daisuke Sano | Panagiotis Katsonis | O. Lichtarge | M. Kimmel | S. Hicks | M. Story | Panagiotis Katsonis | Teng-Kuei Hsu | C. Pickering | A. Osman | C. Caulin | J. Myers | B. Beadle | Alexandra M. Ward | M. Frederick | W. William | H. Skinner | M. Kies | U. Giri | Merrill S Kies | William N William | Adel K El-Naggar | Stephanie C Hicks | Mitchell Frederick | Alexandra Ward | Michael D Story | Curtis R Pickering | Thomas J Ow | Carlos Caulin | Teng-Kuei Hsu | T. Ow | A. Patel | Abdullah A Osman | David M Neskey | Heath D Skinner | Thomas McDonald | Ameeta Patel | John S Yordy | D. Sano | J. Yordy | D. Neskey | A. El-Naggar | A. Ward | David M. Neskey
[1] Angela D. Wilkins,et al. Single nucleotide variations: Biological impact and theoretical interpretation , 2014, Protein science : a publication of the Protein Society.
[2] O. Lichtarge,et al. A formal perturbation equation between genotype and phenotype determines the Evolutionary Action of protein-coding variations on fitness , 2014, Genome research.
[3] Ryan K. Orosco,et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss , 2014, Nature Genetics.
[4] R. Gibbs,et al. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types , 2014, The Journal of pathology.
[5] Olivier Lichtarge,et al. Prediction and experimental validation of enzyme substrate specificity in protein structures , 2013, Proceedings of the National Academy of Sciences.
[6] R. Gibbs,et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. , 2013, Cancer discovery.
[7] Ge Zhou,et al. Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells , 2013, The Laryngoscope.
[8] D. Hayes,et al. Abstract 1117: Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas. , 2013 .
[9] K. Vousden,et al. p53 mutations in cancer , 2013, Nature Cell Biology.
[10] R. Gibbs,et al. Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.
[11] Mei Zhao,et al. Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites , 2011, Clinical Cancer Research.
[12] A. McKenna,et al. The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.
[13] C. R. Leemans,et al. Imaging , Diagnosis , Prognosis Prognostic Significance of Truncating TP 53 Mutations in Head and Neck Squamous Cell Carcinoma , 2011 .
[14] Mei Zhao,et al. Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model , 2010, Head & neck.
[15] Angela D. Wilkins,et al. Evolution: a guide to perturb protein function and networks. , 2010, Current opinion in structural biology.
[16] S. Erdin,et al. Evolutionary trace annotation of protein function in the structural proteome. , 2010, Journal of molecular biology.
[17] Varda Rotter,et al. When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.
[18] J. Myers,et al. Xenograft models of head and neck cancers , 2009, Head & neck oncology.
[19] J. Manola,et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.
[20] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[21] Ming K. Lee,et al. Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53 , 2007, Nucleic acids research.
[22] S. Kato,et al. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. , 2005, Cancer research.
[23] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[24] Handbook of Statistics 23: Advances in Survival Analysis , 2005 .
[25] Xinbin Chen,et al. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes , 2004, Oncogene.
[26] O. Lichtarge,et al. A family of evolution-entropy hybrid methods for ranking protein residues by importance. , 2004, Journal of molecular biology.
[27] S. Kato,et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] O. Lichtarge,et al. Structural clusters of evolutionary trace residues are statistically significant and common in proteins. , 2002, Journal of molecular biology.
[29] John O'Quigley,et al. An application of changepoint methods in studying the effect of age on survival in breast cancer , 1999 .
[30] F. Bosch,et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer , 1998, Oncogene.
[31] S. Goodman,et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. , 1996, Journal of the National Cancer Institute.
[32] F. Cohen,et al. An evolutionary trace method defines binding surfaces common to protein families. , 1996, Journal of molecular biology.
[33] A. Levine,et al. Gain of function mutations in p53 , 1993, Nature Genetics.
[34] S. Henikoff,et al. Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[35] A. Ketcham,et al. Experimental study of metastases. , 1966, JAMA.
[36] A. Jemal,et al. Global Cancer Statistics , 2011 .
[37] John P. Klein,et al. Discretizing a Continuous Covariate in Survival Studies , 2003, Advances in Survival Analysis.
[38] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.